S14 Ep28: Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

In today’s episode, leading experts across oncology specialties previewed the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.Dana M. Chase, MD, a professor of Clinical Obstetrics and Gynecology in the Division of Gynecologic Oncology at UCLA, discussed her excitement to see findings from a phase 1 trial (NCT05403554) investigating NI-1801 in patients with heavily pretreated, mesothelin-expressing platinum-resistant epithelial ovarian cancer.Premal H. Thaker, MD, MS, the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology and director of Gynecologic Oncology Clinical Research at Siteman Cancer Center in Saint Louis, Missouri, discussed the anticipation for findings from a multi-omic analysis of the phase 3 AtTEnd/ENGOT-EN7 trial (NCT03603184) of atezolizumab in patients with endometrial cancer and data demonstrating that the WES-derived Aneuploidy Score may identify patients with mismatch repair–deficient endometrial cancer who derive reduced benefit from immunotherapy.Zev Wainberg, MD, the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research at UCLA, shared his anticipation for new data in gastrointestinal oncology, particularly the overall survival results from the phase 3 MATTERHORN trial (NCT04592913) of durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel in patients with resectable gastric and gastroesophageal cancer, which are expected to provide pivotal updates following previously reported event-free survival outcomes.Sagus Sampath, MD, an associate clinical professor and medical director of the Department of Radiation Oncology at City of Hope in Duarte, California, highlighted the phase 2 NorthStar trial (NCT03410043) evaluating osimertinib (Tagrisso) with or without local consolidative therapy in patients with metastatic EGFR-mutated non–small cell lung cancer (NSCLC).